alendronate has been researched along with Adverse Drug Event in 14 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The medications were pravastatin, a cholesterol-lowering drug for the prevention of cardiovascular disease; alendronate, a bisphosphonate for the treatment and prevention of osteoporosis; and aspirin, which is used for the prevention of cardiovascular disease." | 3.70 | Coverage by the news media of the benefits and risks of medications. ( Bero, L; Henry, D; Lee, K; Mah, C; Moynihan, R; Ross-Degnan, D; Soumerai, SB; Watkins, J, 2000) |
| " And adverse events (AEs), including incidence of neoplasms and infections, were considered as secondary outcomes." | 2.48 | Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. ( Cai, XZ; Guo, C; Lin, T; Shi, MM; Wang, C; Yan, SG; Ying, ZM; Yuan, FZ; Zhao, X, 2012) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Boumil, MM | 1 |
| Beninger, PR | 1 |
| Wolf, MS | 1 |
| Shekelle, P | 1 |
| Choudhry, NK | 1 |
| Agnew-Blais, J | 1 |
| Parker, RM | 1 |
| Shrank, WH | 1 |
| Grosso, A | 1 |
| Douglas, I | 1 |
| Hingorani, A | 1 |
| MacAllister, R | 1 |
| Smeeth, L | 1 |
| Mueller, EA | 1 |
| Kirch, W | 1 |
| Landfeldt, E | 1 |
| Lang, A | 1 |
| Robbins, S | 1 |
| Ström, O | 1 |
| Lin, T | 1 |
| Wang, C | 1 |
| Cai, XZ | 1 |
| Zhao, X | 1 |
| Shi, MM | 1 |
| Ying, ZM | 1 |
| Yuan, FZ | 1 |
| Guo, C | 1 |
| Yan, SG | 1 |
| Shiraki, M | 1 |
| Nakamura, T | 1 |
| Fukunaga, M | 1 |
| Sone, T | 1 |
| Usami, A | 1 |
| Inoue, T | 1 |
| Saag, K | 1 |
| Lindsay, R | 1 |
| Kriegman, A | 1 |
| Beamer, E | 1 |
| Zhou, W | 1 |
| Parfitt, JR | 1 |
| Driman, DK | 1 |
| Harada, A | 1 |
| Moynihan, R | 1 |
| Bero, L | 1 |
| Ross-Degnan, D | 1 |
| Henry, D | 1 |
| Lee, K | 1 |
| Watkins, J | 1 |
| Mah, C | 1 |
| Soumerai, SB | 1 |
3 reviews available for alendronate and Adverse Drug Event
| Article | Year |
|---|---|
Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bon | 2012 |
Pathological effects of drugs on the gastrointestinal tract: a review.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Colitis; Drug-Related Side Effects | 2007 |
[Evidence of alendronate treatment for osteoporosis].
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Colla | 2007 |
2 trials available for alendronate and Adverse Drug Event
| Article | Year |
|---|---|
A multicenter randomized double-masked comparative study of different preparations of alendronate in osteoporosis - monthly (four weeks) intravenous versus once weekly oral administrations.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Algorithms; | 2012 |
A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Resorp | 2007 |
9 other studies available for alendronate and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
The Alendronate Conundrum: Balancing the Competing Influences for Truly Informed Consent About Drug Safety in an Era of Rapid Change.
Topics: Alendronate; Drug-Related Side Effects and Adverse Reactions; Humans; Informed Consent; Pharmaceutic | 2023 |
Variability in pharmacy interpretations of physician prescriptions.
Topics: Alendronate; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Bone Dens | 2009 |
Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Atrial Fibrillation; Atrial Flutter; Bone Density Conservation | 2009 |
[Risks associated with drug therapy. What do patients need to know? What can they do].
Topics: Administration, Intravaginal; Aged; Alendronate; Anticoagulants; Bone Density Conservation Agents; D | 2009 |
Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Substitution; Drug-Rela | 2011 |
Coverage by the news media of the benefits and risks of medications.
Topics: Alendronate; Anticholesteremic Agents; Aspirin; Biomedical Research; Cardiovascular Diseases; Confli | 2000 |